Trial · NCT04187404

A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

NCT04187404, Phase 1, Phase 2, Terminated, Enterome; results first posted 2026-01-30

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma. Trials, record NCT04187404. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04187404

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
NCT number: NCT04187404
Status: Terminated
Phases: Phase 1, Phase 2
Enrollment: 70 participants, actual
Lead sponsor: Enterome
Conditions: Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
Interventions: EO2401, Nivolumab
First posted: 2019-12-05
Last updated: 2026-01-30
Results first posted: 2026-01-30

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Treatment-Emergent Serious Adverse Events Assessment	46 months maximum (from baseline up to study end)	Incidences of treatment-emergent serious adverse events using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.
Primary	Treatment-Emergent Non-Serious Adverse Events	46 months maximum (from baseline up to study end)	Incidences of treatment-emergent non-serious adverse events using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.
Primary	All Cause Mortalities Assessment	46 months maximum (from baseline up to study end)	Incidence of death
Secondary	Evaluation of Progression Free Survival	6 months after treatment start	Progression Free Survival according to iRECIST criteria at 6 months
Secondary	Evaluation of Survival	46 months maximum (from baseline up to study end)	Overall survival, defined as the time interval from the date of first study treatment administration to the date of death due to any cause
Secondary	Percentage of Patients With Immunogenicity Against EO2401	7 weeks after treatment start	Expansion of specific T cells comparing samples taken at baseline versus on treatment in an individual patient determining if the patient has a positive response to peptides that compose EO2401, or not. EO2401 immunogenicity is assessed by interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISpot) (IVS and ex vivo).

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Treatment-Emergent Serious Adverse Events Assessment	46 months maximum (from baseline up to study end)		Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Treatment-Emergent Non-Serious Adverse Events	46 months maximum (from baseline up to study end)		Participants	COUNT_OF_PARTICIPANTS
PRIMARY	All Cause Mortalities Assessment	46 months maximum (from baseline up to study end)		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Evaluation of Progression Free Survival	6 months after treatment start		months	MEDIAN
SECONDARY	Evaluation of Survival	46 months maximum (from baseline up to study end)		months	MEDIAN
SECONDARY	Percentage of Patients With Immunogenicity Against EO2401	7 weeks after treatment start	Patient is in C2A-III were treated with nivolumab only (not EO2401)	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group42

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Treatment-Emergent Serious Adverse Events Assessment	Cohort 2A (Non-randomized)	5	Participants
Treatment-Emergent Serious Adverse Events Assessment	Randomized Extension of Cohort 2A (3 Arms): C2A-I	4	Participants
Treatment-Emergent Serious Adverse Events Assessment	Randomized Extension of Cohort 2A (3 Arms): C2A-II	1	Participants
Treatment-Emergent Serious Adverse Events Assessment	Randomized Extension of Cohort 2A (3 Arms): C2A-III	0	Participants
Treatment-Emergent Serious Adverse Events Assessment	Cohort 2B (Non-randomized)	1	Participants
Treatment-Emergent Serious Adverse Events Assessment	Cohort 3A (Non-randomized)	4	Participants
Treatment-Emergent Serious Adverse Events Assessment	Cohort 3B (Non-randomized)	2	Participants
Treatment-Emergent Non-Serious Adverse Events	Cohort 2A (Non-randomized)	26	Participants
Treatment-Emergent Non-Serious Adverse Events	Randomized Extension of Cohort 2A (3 Arms): C2A-I	13	Participants
Treatment-Emergent Non-Serious Adverse Events	Randomized Extension of Cohort 2A (3 Arms): C2A-II	2	Participants

1 to 10 of 42Source ClinicalTrials.gov

See all 42 results by group

Participant flow28

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Cohort 2A (Non-randomized)	26
Overall Study	STARTED	Randomized Extension of Cohort 2A (3 Arms): C2A-I	13
Overall Study	STARTED	Randomized Extension of Cohort 2A (3 Arms): C2A-II	2
Overall Study	STARTED	Randomized Extension of Cohort 2A (3 Arms): C2A-III	4
Overall Study	STARTED	Cohort 2B (Non-randomized)	7
Overall Study	STARTED	Cohort 3A (Non-randomized)	13
Overall Study	STARTED	Cohort 3B (Non-randomized)	5
Overall Study	Started and Originally Enrolled in Cohort 1 (Safety lead-in).	Cohort 2A (Non-randomized)	2
Overall Study	Started and Originally Enrolled in Cohort 1 (Safety lead-in).	Randomized Extension of Cohort 2A (3 Arms): C2A-I	0
Overall Study	Started and Originally Enrolled in Cohort 1 (Safety lead-in).	Randomized Extension of Cohort 2A (3 Arms): C2A-II	0

1 to 10 of 28Source ClinicalTrials.gov

See all 28 participant flow

Adverse events1,883

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	Cohort 2A (Non-randomized)	6	26	6
other	Anaemia	Blood and lymphatic system disorders	Randomized Extension of Cohort 2A (3 Arms): C2A-I	1	13	1
other	Anaemia	Blood and lymphatic system disorders	Randomized Extension of Cohort 2A (3 Arms): C2A-II	0	2	0
other	Anaemia	Blood and lymphatic system disorders	Randomized Extension of Cohort 2A (3 Arms): C2A-III	0	4	0
other	Anaemia	Blood and lymphatic system disorders	Cohort 2B (Non-randomized)	2	7	2
other	Anaemia	Blood and lymphatic system disorders	Cohort 3A (Non-randomized)	5	13	5
other	Anaemia	Blood and lymphatic system disorders	Cohort 3B (Non-randomized)	1	5	1
other	Leukocytosis	Blood and lymphatic system disorders	Cohort 2A (Non-randomized)	1	26	1
other	Leukocytosis	Blood and lymphatic system disorders	Randomized Extension of Cohort 2A (3 Arms): C2A-I	0	13	0
other	Leukocytosis	Blood and lymphatic system disorders	Randomized Extension of Cohort 2A (3 Arms): C2A-II	0	2	0

1 to 10 of 1,883Source ClinicalTrials.gov

See all 1,883 adverse events

Adverse event totals21

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Cohort 2A (Non-randomized)	21	26
Total, all-cause mortality	Randomized Extension of Cohort 2A (3 Arms): C2A-I	5	13
Total, all-cause mortality	Randomized Extension of Cohort 2A (3 Arms): C2A-II	1	2
Total, all-cause mortality	Randomized Extension of Cohort 2A (3 Arms): C2A-III	2	4
Total, all-cause mortality	Cohort 2B (Non-randomized)	6	7
Total, all-cause mortality	Cohort 3A (Non-randomized)	9	13
Total, all-cause mortality	Cohort 3B (Non-randomized)	0	5
Total, other adverse events	Cohort 2A (Non-randomized)	26	26
Total, other adverse events	Randomized Extension of Cohort 2A (3 Arms): C2A-I	13	13
Total, other adverse events	Randomized Extension of Cohort 2A (3 Arms): C2A-II	2	2

1 to 10 of 21Source ClinicalTrials.gov

See all 21 adverse event totals

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04187404

GET https://conductscience.org/api/trials/v1/NCT04187404/results?page=2

API reference For AI assistants